A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer

Introduction Radium-223 (Xofigo, Bayer Pharmaceuticals Inc., Whippany, NJ) has been shown to increase overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC), via the phase 3 ALpharadin in SYMPtomatic Prostate CAncer (ASLYMPCA) study. Hematologic side effects of rad...

Descripción completa

Detalles Bibliográficos
Autores principales: Skelton, William P, Dibenedetto, Samantha W, Pang, Shiyi S, Pan, Kelsey, Barish, Jacob L, Nwosu-Iheme, Adaeze, Dang, Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047342/
https://www.ncbi.nlm.nih.gov/pubmed/32140364
http://dx.doi.org/10.7759/cureus.6806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047342/
https://www.ncbi.nlm.nih.gov/pubmed/32140364
http://dx.doi.org/10.7759/cureus.6806

Ejemplares similares